临床诊断与活检证实的早期非小细胞肺癌立体定向体部放疗后的生存:系统综述与Meta分析
该系统综述与Meta分析比较临床诊断与活检证实的早期NSCLC患者接受SBRT后的生存结局。比较性研究显示活检证实组3年总生存及2年、5年癌症特异性生存低于临床诊断组,但5年总生存两组相同;汇总估计显示活检组3年无病生存和2年癌症特异性生存较低。
要点
- 活检证实组3年总生存低于临床诊断组,但5年总生存两组相同
- 活检证实组2年和5年癌症特异性生存低于临床诊断组
- 汇总估计中活检证实组3年无病生存和2年癌症特异性生存较低
核心结论
- 接受SBRT的疑似早期NSCLC患者中,有病理证实与仅有临床诊断者的肿瘤学结局存在差异。
- 这些结果强调获得恶性肿瘤病理证据的重要性。
研究设计与样本
- 系统综述与Meta分析,检索主要数据库中的试验和队列研究,不限制发表状态或语言。
- 由两名独立研究者筛选和选择合格研究。
- 初检识别11195条非重复记录,经标题和摘要筛选后识别1051条可能合格记录,最终纳入43篇文章。
- 结局为总生存、癌症特异性生存和无病生存。
- 采用逆方差法和随机效应法评估汇总生存估计。
主要发现
- 比较性研究显示活检证实组3年总生存低于临床诊断组。
- 比较性研究显示活检证实组2年和5年癌症特异性生存低于临床诊断组。
- 5年总生存两组相同。
- 汇总估计显示活检证实组3年无病生存低于临床诊断组。
- 汇总估计显示活检证实组2年癌症特异性生存低于临床诊断组。
关键数值与推荐
- 比较性研究:活检证实组3年总生存低于临床诊断组。
- 比较性研究:活检证实组2年和5年癌症特异性生存低于临床诊断组。
- 比较性研究:5年总生存两组相同。
- 汇总估计:活检证实组3年无病生存低于临床诊断组。
- 汇总估计:活检证实组2年癌症特异性生存低于临床诊断组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Stereotactic body radiation therapy (SBRT) is a promising curative treatment for early-stage NSCLC. It is unclear if survival outcomes for SBRT are influenced by a lack of pathological confirmation of malignancy and staging of disease in these patients. In this systematic review and meta-analysis, we assess survival outcomes after SBRT in studies with patients with clinically diagnosed versus biopsy-proven early-stage NSCLC. METHODS: The main databases were searched for trials and cohort studies without restrictions to publication status or language. Two independent researchers performed the screening and selection of eligible studies. Outcomes were overall survival, cancer-specific survival, and disease-free survival. The inverse variance method and the random effects method for meta-analysis were used to assess pooled survival estimates. RESULTS: A total of 11,195 nonduplicate records were identified by the original search strategy. After screening by title and abstract, 1051 potentially eligible records were identified. A total of 43 articles were included. The comparative studies showed lower 3-year overall survival and lower 2-year and 5-year cancer-specific survival for biopsy-proven disease compared to clinical disease. However, 5-year overall survival was the same for both groups. For the pooled estimates, 3-year disease-free survival and 2-year cancer-specific survival were lower for biopsied disease. CONCLUSIONS: Results of this systematic review and meta-analysis show a discrepancy in oncological outcomes for patients undergoing SBRT for suspected early-stage NSCLC in whom there is pathologic conformation of malignancy and those who there is only a clinical diagnose of NSCLC. These results emphasize the importance of obtaining pathologic proof of malignancy.
引用
- IJsseldijk MA, Shoni M, Siegert C, et al. Survival After Stereotactic Body Radiation Therapy for Clinically Diagnosed or Biopsy-Proven Early-Stage NSCLC: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2019. PMID: 30721798. doi:10.1016/j.jtho.2018.12.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。